Insmed, a biopharmaceutical specialist in rare diseases, is stealing the spotlight in 2025 with a stunning 62% gain, ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

The adoption of the new “clinical obesity” definition alters prevalence estimates of obesity in many parts of the world ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the last reported quarter, the company beat earnings expectations by 17.8%. The ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

Osborne Clarke has posted a global revenue increase of 4% to €547.5 million for the 2024/25 financial year. The firm ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

On July 24, Emily Roland, Manulife John Hancock Investments co-chief investment strategist, appeared on CNBC’s ...

Aquent is a multinational staffing and recruiting agency that places design and marketing professionals in permanent and ...

The firms posted increases in revenue and profit per equity partner, with both giving a nod to their IP expertise ...

Nasdaq and S&P 500 hit record highs on Wall Street on Tuesday, 29 July 2025, as investors focused on the second-quarter results and the upcoming US Federal Reserve (Fed) policy. Companies like Sofi, ...